Xencor | XNCR - Operating Profit



Xencor reported $-33172000 in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
Amgen USD 2.66B 1.37B Jun/2025
Arrowhead Research USD -165550000 546.75M Jun/2025
AstraZeneca USD 3.51B 166M Jun/2025
Biogen USD 851.8M 540.6M Jun/2025
Bristol-Myers Squibb USD 3.77B 366M Jun/2025
Cytokinetics USD -111506000 44.12M Jun/2025
GlaxoSmithKline GBP 2.02B 193M Jun/2025
J&J USD 6.94B 6.69B Jun/2025
MacroGenics USD -36760000 20.17M Jun/2025
Merck USD 6.36B 494M Jun/2025
Novartis USD 4.86B 201M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
Regeneron Pharmaceuticals USD 1.08B 487.8M Jun/2025
Roche Holding CHF 4.39B 1.04B Dec/2024
Xencor USD -33172000 10.01M Jun/2025